{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:46Z","timestamp":1740107746698,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802126","81671608"],"award-info":[{"award-number":["81802126","81671608"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To analyze the relative factors of improvement in disease activity (IDA) after first hospitalized treatment based on the systemic lupus erythematosus disease activity index (SLEDAI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 1069 adult systemic lupus erythematosus (SLE) patients who were hospitalized for the first time in 26 hospitals in Jiangsu Province from 1999 to 2009 were retrospectively analyzed. SLEDAI decrease\u2009\u2265\u20094 during hospitalization was identified as IDA. Relative factors of IDA were assessed by univariate and multivariate logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 783 (73.2%) adult SLE patients showed IDA after the first hospitalization, while the remaining patients (<jats:italic>n<\/jats:italic>\u2009=\u2009286) were in the non-IDA group. The IDA group had higher SLEDAI at admission; fewer patients had SLICC\/ACR damage index (SDI)\u2009\u2265\u20091, comorbidities at admission, especially Sj\u00f6gren\u2019s syndrome, abnormal serum creatinine, and glomerular filtration rate. More patients had mucocutaneous and musculoskeletal involvements, leukopenia, increased C-reactive protein, anti-dsDNA antibody positive, and hypocomplementemia at admission and were treated with methotrexate and leflunomide during hospitalization. After multivariate logistic regression analysis, <jats:italic>SDI<\/jats:italic>\u2009\u2265\u20091 (<jats:italic>P<\/jats:italic>\u2009=\u20090.005) and combined with Sj\u00f6gren\u2019s syndrome (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) at admission had negative association with IDA. Musculoskeletal involvement (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), anti-dsDNA antibody positive (<jats:italic>P<\/jats:italic>\u2009=\u20090.012), hypocomplementemia (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), and use of leflunomide (<jats:italic>P<\/jats:italic>\u2009=\u20090.030) were significantly related with IDA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Organ damage or comorbidities at admission were adverse to SLE improvement. Anti-dsDNA antibody positive, hypocomplementemia, musculoskeletal involvements, and leflunomide treatment had positive association with IDA of SLE.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Organ damage or comorbidities at admission were negatively correlated with SLE improvement.<\/jats:italic>\u2022 <jats:italic>Anti-dsDNA antibody positivity, hypocomplementemia, musculoskeletal involvements, and leflunomide treatment were positively associated with SLE improvement.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06289-7","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T07:02:39Z","timestamp":1658127759000},"page":"3355-3362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of improvement in disease activity in first hospitalized patients with systemic lupus erythematosus: a multicenter retrospective study of a Chinese cohort"],"prefix":"10.1007","volume":"41","author":[{"given":"Mei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyou","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuwan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaixia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaohong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanyun","family":"Da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaojia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-2755","authenticated-orcid":false,"given":"Huayong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"6289_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/annrheumdis-2018-214802","volume":"78","author":"K Tselios","year":"2019","unstructured":"Tselios K, Gladman DD, Sheane BJ et al (2019) All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971\u20132013). Ann Rheum Dis 78:802\u2013806. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214802","journal-title":"Ann Rheum Dis"},{"key":"6289_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2017-211613","volume":"77","author":"M Zen","year":"2018","unstructured":"Zen M, Iaccarino L, Gatto M et al (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77:104\u2013110. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211613","journal-title":"Ann Rheum Dis"},{"key":"6289_CR3","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288\u2013291","journal-title":"J Rheumatol"},{"key":"6289_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","volume":"11","author":"KMAC Luijten","year":"2012","unstructured":"Luijten KMAC, Tekstra J, Bijlsma JWJ et al (2012) The systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 11:326\u2013329. https:\/\/doi.org\/10.1016\/j.autrev.2011.06.011","journal-title":"Autoimmun Rev"},{"key":"6289_CR5","first-page":"2256","volume":"29","author":"JT Merrill","year":"2002","unstructured":"Merrill JT (2002) Measuring disease activity in systemic lupus: progress and problems. J Rheumatol 29:2256\u20132257","journal-title":"J Rheumatol"},{"key":"6289_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3899\/jrheum.101088","volume":"38","author":"X Feng","year":"2011","unstructured":"Feng X, Zou Y, Pan W et al (2011) Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China. J Rheumatol 38:1289\u20131295. https:\/\/doi.org\/10.3899\/jrheum.101088","journal-title":"J Rheumatol"},{"key":"6289_CR7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism 25:1271\u20131277. https:\/\/doi.org\/10.1002\/art.1780251101","journal-title":"Arthritis and rheumatism"},{"key":"6289_CR8","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725\u20131725. https:\/\/doi.org\/10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"key":"6289_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis and rheumatism 39:363\u2013369. https:\/\/doi.org\/10.1002\/art.1780390303","journal-title":"Arthritis and rheumatism"},{"key":"6289_CR10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/art.40511","volume":"70","author":"A Doria","year":"2018","unstructured":"Doria A, Stohl W, Schwarting A et al (2018) Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis & rheumatology (Hoboken, NJ) 70:1256\u20131264. https:\/\/doi.org\/10.1002\/art.40511","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"6289_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343\u20131349. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200937","journal-title":"Ann Rheum Dis"},{"key":"6289_CR12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/art.41253","volume":"72","author":"M Gatto","year":"2020","unstructured":"Gatto M, Saccon F, Zen M et al (2020) Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting. Arthritis & rheumatology (Hoboken, NJ) 72:1314\u20131324. https:\/\/doi.org\/10.1002\/art.41253","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"6289_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G et al (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"6289_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","volume":"16","author":"D Pisetsky","year":"2020","unstructured":"Pisetsky D, Lipsky P (2020) New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol 16:565\u2013579. https:\/\/doi.org\/10.1038\/s41584-020-0480-7","journal-title":"Nat Rev Rheumatol"},{"key":"6289_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-019-2056-y","volume":"21","author":"A Sohrabian","year":"2019","unstructured":"Sohrabian A, Parodis I, Carlstr\u00f6mer-Berth\u00e9n N et al (2019) Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther 21:259. https:\/\/doi.org\/10.1186\/s13075-019-2056-y","journal-title":"Arthritis Res Ther"},{"key":"6289_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-021-01051-x","author":"C Sieiro Santos","year":"2021","unstructured":"Sieiro Santos C, Moriano Morales C, \u00c1lvarez Castro C et al (2021) Polyautoimmunity in systemic lupus erythematosus: secondary Sjogren syndrome. Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-021-01051-x","journal-title":"Z Rheumatol"},{"key":"6289_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","volume":"74","author":"M Zen","year":"2015","unstructured":"Zen M, Iaccarino L, Gatto M et al (2015) Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 74:2117\u20132122. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207347","journal-title":"Ann Rheum Dis"},{"key":"6289_CR18","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3899\/jrheum.131137","volume":"41","author":"AJ Steiman","year":"2014","unstructured":"Steiman AJ, Urowitz MB, Iba\u00f1ez D et al (2014) Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 41:1808\u20131816. https:\/\/doi.org\/10.3899\/jrheum.131137","journal-title":"J Rheumatol"},{"key":"6289_CR19","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/annrheumdis-2016-210382","volume":"76","author":"CC Mok","year":"2017","unstructured":"Mok CC, Ho LY, Tse SM et al (2017) Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 76:1420\u20131425. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210382","journal-title":"Ann Rheum Dis"},{"key":"6289_CR20","doi-asserted-by":"publisher","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","volume":"2","author":"F Tamirou","year":"2015","unstructured":"Tamirou F, Lauwerys BR, Dall\u2019Era M et al (2015) A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2:e000123. https:\/\/doi.org\/10.1136\/lupus-2015-000123","journal-title":"Lupus Sci Med"},{"key":"6289_CR21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.39026","volume":"67","author":"M Dall'Era","year":"2015","unstructured":"Dall\u2019Era M, Cisternas MG, Smilek DE et al (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis & rheumatology (Hoboken, NJ) 67:1305\u20131313. https:\/\/doi.org\/10.1002\/art.39026","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"doi-asserted-by":"publisher","unstructured":"Carri\u00f3n-Barber\u00e0 I, Polino L, Mej\u00eda-Torres M, et al. Leflunomide: A safe and effective alternative in systemic lupus erythematosus. Autoimmunity reviews 2021: 102960 https:\/\/doi.org\/10.1016\/j.autrev.2021.102960.","key":"6289_CR22","DOI":"10.1016\/j.autrev.2021.102960"},{"key":"6289_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","volume":"38","author":"M Zhang","year":"2019","unstructured":"Zhang M, Qi C, Zha Y et al (2019) Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin Rheumatol 38:859\u2013867. https:\/\/doi.org\/10.1007\/s10067-018-4348-z","journal-title":"Clin Rheumatol"},{"key":"6289_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/0961203308089408","volume":"17","author":"H Wang","year":"2008","unstructured":"Wang H, Cui T, Hou F et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17:638\u2013644. https:\/\/doi.org\/10.1177\/0961203308089408","journal-title":"Lupus"},{"key":"6289_CR25","first-page":"4423","volume":"21","author":"QS Zhou","year":"2017","unstructured":"Zhou QS, Hu J, Hu H (2017) Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs. Eur Rev Med Pharmacol Sci 21:4423\u20134430","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6289_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144548","volume":"10","author":"H Cao","year":"2015","unstructured":"Cao H, Rao Y, Liu L et al (2015) The efficacy and safety of leflunomide for the treatment of lupus nephritis in Chinese patients: systematic review and meta-analysis. PLoS ONE 10:e0144548. https:\/\/doi.org\/10.1371\/journal.pone.0144548","journal-title":"PLoS ONE"},{"key":"6289_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.776879","volume":"12","author":"S Fuentelsaz-Romero","year":"2021","unstructured":"Fuentelsaz-Romero S, Barrio-Alonso C, Garc\u00eda Campos R et al (2021) The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis. Front Immunol 12:776879. https:\/\/doi.org\/10.3389\/fimmu.2021.776879","journal-title":"Front Immunol"},{"key":"6289_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0961203313519159","volume":"23","author":"R Sakthiswary","year":"2014","unstructured":"Sakthiswary R, Suresh E (2014) Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23:225\u2013235. https:\/\/doi.org\/10.1177\/0961203313519159","journal-title":"Lupus"},{"key":"6289_CR29","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/s0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M (2019) Management strategies and future directions for systemic lupus erythematosus in adults. Lancet (London, England) 393:2332\u20132343. https:\/\/doi.org\/10.1016\/s0140-6736(19)30237-5","journal-title":"Lancet (London, England)"},{"key":"6289_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"6289_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3899\/jrheum.180433","volume":"46","author":"MF Ugarte-Gil","year":"2019","unstructured":"Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ et al (2019) Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multiethnic, multinational Latin American cohort. J Rheumatol 46:1299\u20131308. https:\/\/doi.org\/10.3899\/jrheum.180433","journal-title":"J Rheumatol"},{"key":"6289_CR32","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1007\/s10067-018-4312-y","volume":"37","author":"W Zhang","year":"2018","unstructured":"Zhang W, Wang F, Wang H et al (2018) Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases. Clin Rheumatol 37:3337\u20133344. https:\/\/doi.org\/10.1007\/s10067-018-4312-y","journal-title":"Clin Rheumatol"},{"key":"6289_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.666971","volume":"12","author":"S Piantoni","year":"2021","unstructured":"Piantoni S, Regola F, Masneri S et al (2021) Characterization of B- and T-cell compartment and B-cell related factors belonging to the TNF\/TNFR superfamily in patients with clinically active systemic lupus erythematosus: baseline BAFF serum levels are the strongest predictor of response to belimumab after twelve months of therapy. Front Pharmacol 12:666971. https:\/\/doi.org\/10.3389\/fphar.2021.666971","journal-title":"Front Pharmacol"},{"doi-asserted-by":"publisher","unstructured":"Koelmeyer R, Nim HT, Nikpour M, et al. 2020 High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Sci Med; 7. https:\/\/doi.org\/10.1136\/lupus-2019-000372.","key":"6289_CR34","DOI":"10.1136\/lupus-2019-000372"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T09:13:27Z","timestamp":1665738807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6289"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06289-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}